HCPCS Level IIdrugActive
J1302
Inj, sutimlimab-jome, 10 mg
BETOS: O1E
Effective: 2022-10-01
Referenced in 1 policies
Description
Injection, sutimlimab-jome, 10 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Enjaymo
Manufacturer
Recordati Rare Diseases Inc.
HCPCS Dosage
10 MG
Billing Units
110.0000
2
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.